This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Additional Minocycline Pleurodesis After Thoracoscopic Procedures for Primary Spontaneous Pneumothorax

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2001 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
National Science Council, Taiwan
Information provided by:
National Taiwan University Hospital Identifier:
First received: September 8, 2005
Last updated: October 19, 2005
Last verified: June 2001
To test if additional minocycline pleurodesis after thoracoscopic procedures can reduce the rates of ipsilateral recurrence for patients with primary spontaneous pneumothorax.

Condition Intervention Phase
Pneumothorax Drug: intrapleural minocycline instillation Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III Study of Additional Minocycline Pleurodesis After Video-Assisted Thoracoscopic Surgery for Primary Spontaneous Pneumothorax

Resource links provided by NLM:

Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • The primary end point was rates of ipsilateral recurrence after the operation.

Secondary Outcome Measures:
  • safety of minocycline
  • early postoperative results of minocycline
  • long-term complication of minocycline
  • long-term effect on pulmonary function of minocycline pleurodesis

Estimated Enrollment: 200
Study Start Date: June 2001
Estimated Study Completion Date: March 2005
  Show Detailed Description


Ages Eligible for Study:   10 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients requiring VATS caused by recurrent, persistent, or contralateral spontaneous pneumothorax as well as by spontaneous hemopneumothorax were eligible for this study.

Exclusion Criteria:

  • greater than 50 years of age, with underlying pulmonary disease, previous ipsilateral thoracic operation, allergy to tetracycline or minocycline, and unwilling to receive randomization.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00154895

Contact: Jin-Shing Chen, MD, PhD 886-2-23123456 ext 5178
Contact: Yung-Chie Lee, MD, PhD 886-2-23123456 ext 5070

Yung-Chie Lee Recruiting
Taipei, Taiwan, 100
Contact: Jin-Shing Chen, MD, PhD    886-2-23123456 ext 5178   
Sub-Investigator: Jin-Shing Chen, MD, PhD         
Principal Investigator: Yung-Chie Lee, MD, PhD         
Sponsors and Collaborators
National Taiwan University Hospital
National Science Council, Taiwan
Study Chair: Yung-Chie Lee, MD, PhD Natinal Taiwan University Hospital
  More Information Identifier: NCT00154895     History of Changes
Other Study ID Numbers: 921204
Study First Received: September 8, 2005
Last Updated: October 19, 2005

Keywords provided by National Taiwan University Hospital:
primary spontaneous pneumothorax
clinical trial

Additional relevant MeSH terms:
Pleural Diseases
Respiratory Tract Diseases
Anti-Bacterial Agents
Anti-Infective Agents processed this record on September 21, 2017